MacuLogix™, Inc., a company that equips eye care professionals with the instrument, tools and education needed to effectively diagnose and treat patients with age-related macular degeneration (AMD), announces that Health Canada has issued a medical device licence for the AdaptDx Pro™ dark adaptometer and the device is now available for purchase in Canada (through LUVO Medical Technologies Inc.) and through a distribution partner Clarion Medical Technologies.
“The AdaptDx Pro is changing the future of AMD by eliminating barriers to diagnosis and management,” says MacuLogix Co-founder and Chief Technology Officer Gregory Jackson, Ph.D.
The company’s original AdaptDx™ table-top dark adaptometer has been used by more than 1,000 US eye care professionals to help identify and monitor AMD. The new AdaptDx Pro includes all the functionality of the company’s table-top unit. As a self-contained wearable headset, the AdaptDx Pro requires no dark room or external computer and features an artificial intelligence-driven onboard technician named Theia™. Theia communicates in local languages (including English and Canadian French) and facilitates a reliable testing experience using automated instructions and adaptive feedback spoken directly to the patient.
“The ability to detect the earliest biomarker of AMD will help Canadian eye care providers to better manage the growing numbers of the disease,” says Bryan Gosse, Director of Vision at Clarion Medical Technologies. “We are excited to be in a position to bring this advancement to the Canadian market.”